Helius Medical Technologies Inc (NASDAQ: HSDT)’s stock price has gone rise by 26.35 in comparison to its previous close of 0.49, however, the company has experienced a 36.19% increase in its stock price over the last five trading days. globenewswire.com reported 2024-11-18 that NEWTOWN, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today provided updates on its efforts to achieve fair market access for its Portable Neuromodulation Stimulator (PoNS) device and announced plans to host a business update call today at 9:00am ET.
Is It Worth Investing in Helius Medical Technologies Inc (NASDAQ: HSDT) Right Now?
The stock has a 36-month beta value of 1.69. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for HSDT is 3.67M, and at present, short sellers hold a 2.59% of that float. On December 03, 2024, the average trading volume of HSDT was 451.44K shares.
HSDT’s Market Performance
HSDT’s stock has seen a 36.19% increase for the week, with a 21.74% rise in the past month and a -27.93% fall in the past quarter. The volatility ratio for the week is 16.91%, and the volatility levels for the past 30 days are at 13.19% for Helius Medical Technologies Inc The simple moving average for the past 20 days is 19.82% for HSDT’s stock, with a -70.22% simple moving average for the past 200 days.
Analysts’ Opinion of HSDT
Many brokerage firms have already submitted their reports for HSDT stocks, with Noble Capital Markets repeating the rating for HSDT by listing it as a “Outperform.” The predicted price for HSDT in the upcoming period, according to Noble Capital Markets is $20 based on the research report published on March 24, 2021 of the previous year 2021.
HSDT Trading at 15.23% from the 50-Day Moving Average
After a stumble in the market that brought HSDT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.50% of loss for the given period.
Volatility was left at 13.19%, however, over the last 30 days, the volatility rate increased by 16.91%, as shares surge +22.53% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.00% lower at present.
During the last 5 trading sessions, HSDT rose by +36.80%, which changed the moving average for the period of 200-days by -89.70% in comparison to the 20-day moving average, which settled at $0.5152. In addition, Helius Medical Technologies Inc saw -92.32% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HSDT starting from ANDREEFF DANE, who purchase 5,000 shares at the price of $8.10 back on Dec 14 ’23. After this action, ANDREEFF DANE now owns 16,512 shares of Helius Medical Technologies Inc, valued at $40,475 using the latest closing price.
Stock Fundamentals for HSDT
Current profitability levels for the company are sitting at:
- -25.9 for the present operating margin
- -0.06 for the gross margin
The net margin for Helius Medical Technologies Inc stands at -17.65. The total capital return value is set at -3.18. Equity return is now at value -259.79, with -122.71 for asset returns.
Based on Helius Medical Technologies Inc (HSDT), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -465.09.
Currently, EBITDA for the company is -12.11 million with net debt to EBITDA at 0.27. When we switch over and look at the enterprise to sales, we see a ratio of -2.28. The receivables turnover for the company is 0.96for trailing twelve months and the total asset turnover is 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.61.
Conclusion
To sum up, Helius Medical Technologies Inc (HSDT) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
